Axsome Therapeutics (AXSM) Change in Accured Expenses (2015 - 2026)

Axsome Therapeutics has reported Change in Accured Expenses for 12 years, with the latest figure at $17.2 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 2006.23% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.2 million (up 53.38% YoY) and the FY2025 annual result came in at $83.7 million, up 49.37% from the prior year.
• Change in Accured Expenses rose to $17.2 million in Q1 2026 per AXSM's latest filing, from $7.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $54.2 million in Q3 2025 and troughed at -$8.4 million in Q1 2024.
• A 5-year average of $14.0 million and a median of $11.4 million in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 8238.14% in 2022, then slumped 217.81% in 2024.
• Over 5 years, Change in Accured Expenses stood at $13.2 million in 2022, then retreated by 13.91% to $11.4 million in 2023, then soared by 125.95% to $25.7 million in 2024, then plunged by 72.05% to $7.2 million in 2025, then soared by 140.16% to $17.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $17.2 million, $7.2 million, and $54.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.